-
Merck gets USFDA nod for KEYTRUDA as adjuvant treatment for non-small cell lung cancer
30 Jan 2023 09:43 GMT
… IIIA non-small cell lung cancer. Unfortunately, many of … with non-small cell lung cancer following surgery and adjuvant … with non-small cell lung cancer.”
"With this approval … for surgical resection or definitive chemoradiation, or metastatic; and …
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:12 GMT
… non-small cell lung cancer following surgery and … (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … resection or definitive chemoradiation either:
in combination …
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:06 GMT
… non-small cell lung cancer following surgery and … (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … resection or definitive chemoradiation either:
in combination …
-
Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
24 Jan 2023 11:55 GMT
… Keywords: non-small cell lung cancer, ALK, alectinib, drug … IIIB. She received concurrent chemoradiation (CCRT) (60 Gy … and extravascular hemolysis in lung cancer patients receiving alectinib. … positive non-small-cell lung cancer. Lung Cancer. 2020;139:195–199 …
-
Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients Treated with Definitive Chemoradiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma
30 Jan 2023 11:05 GMT
… the prognosis of patients with lung cancer, liver cancer, colorectal cancer, head … , Chang BW. Current strategies in chemoradiation for esophageal cancer. J Gastrointest … and IIIB) non-small cell lung cancer treated with combined modality therapy …
-
US FDA approves Keytruda as adjuvant treatment following surgical resection and platinum─based chemotherapy for patients with stage IB (T2a =4 centimeters), II, or IIIA NSCLC
30 Jan 2023 07:49 GMT
… non-small cell lung cancer following surgery and … surgical resection or definitive chemoradiation, or metastatic; and … Oncology Platform (ETOP).
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer …
-
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
11 Nov 2022 13:34 GMT
… not progressed after chemoradiation therapy based on … for people with lung cancer, including and beyond … @AstraZenecaUS.
References
Lungevity. Lung Cancer Statistics. Available at: https … -advocates/lung-cancer-awareness/lung-cancer-statistics#1. …
-
AstraZeneca: FDA OKs Imfinzi + Imjudo With Chemotherapy For Metastatic Non-small Cell Lung Cancer
11 Nov 2022 07:30 GMT
… IV (metastatic) non-small cell lung cancer or NSCLC.
The approval was … disease has not progressed after chemoradiation therapy based on the PACIFIC … of extensive-stage small cell lung cancer (ES-SCLC) based on the …
-
Imfinzi and Imjudo with chemotherapy approved in US for patients with metastatic non-small cell lung cancer
11 Nov 2022 07:15 GMT
… MD, Director of Lung Cancer Research, Sarah Cannon Research … Metastatic non-small cell lung cancer remains a significant treatment … not progressed after chemoradiation therapy based on … improvements for people with lung cancer, including and beyond treatment …
-
FDA approves Libtayo with chemotherapy for advanced non-small cell lung cancer
10 Nov 2022 02:57 GMT
… of advanced non-small cell lung cancer. Cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals … for surgical resection or definitive chemoradiation. "This second FDA approval … in advanced non-small cell lung cancer greatly broadens the scope in …
About
© 1995-2023